Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2021 2
2022 5
2023 4
2024 4
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge.
Binayke A, Zaheer A, Vishwakarma S, Sharma P, Dandotiya J, Raghavan S, Gosain M, Singh S, Chattopadhyay S, Kaushal J, Madan U, Kshetrapal P, Batra G, Wadhwa N, Pandey AK, Bhatnagar S, Garg PK, Awasthi A. Binayke A, et al. J Med Virol. 2024 Aug;96(8):e29877. doi: 10.1002/jmv.29877. J Med Virol. 2024. PMID: 39169721
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Singh C, Rao A V, Basu I, Kumar KAA, Pandey AK. Thuluva S, et al. Among authors: binayke a. Hum Vaccin Immunother. 2023 Dec 31;19(1):2203632. doi: 10.1080/21645515.2023.2203632. Epub 2023 Apr 27. Hum Vaccin Immunother. 2023. PMID: 37113012 Free PMC article. Clinical Trial.
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla RR, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Narang M, Nanjappa P, Mahantshetti N, Swarup Garg B, Pandey AK. Thuluva S, et al. Among authors: binayke a. Vaccine. 2022 Nov 22;40(49):7130-7140. doi: 10.1016/j.vaccine.2022.10.045. Epub 2022 Oct 31. Vaccine. 2022. PMID: 36328879 Clinical Trial.
19 results